Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment ; volume:2 ; number:1 ; day:18 ; month:2 ; year:2014 ; pages:1-14 ; date:12.2014
Journal for ImmunoTherapy of Cancer ; 2, Heft 1 (18.2.2014), 1-14, 12.2014
- Creator
-
Spranger, Stefani
- Contributor
-
Koblish, Holly K.
Horton, Brendan
Scherle, Peggy A.
Newton, Robert
Gajewski, Thomas F.
SpringerLink (Online service)
- DOI
-
10.1186/2051-1426-2-3
- URN
-
urn:nbn:de:1111-2016072656828
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Spranger, Stefani
- Koblish, Holly K.
- Horton, Brendan
- Scherle, Peggy A.
- Newton, Robert
- Gajewski, Thomas F.
- SpringerLink (Online service)
Other Objects (12)
Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Regulation of PD-L1 expression in the tumor microenvironment
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Regulation of PD-L1 expression in the tumor microenvironment
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Regulation of PD-L1 expression in the tumor microenvironment
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer